The European Medicines Agency’s Irmgard Eichler talks to Karen Finn about the programme’s progress.
Nearly a year has elapsed since companies seeking marketing authorisations in the European Union were required to begin submitting paediatric investigation plans or requests for waivers/deferrals under the Paediatric Regulation 1, and nearly two years have passed since the European Medicines Agency’s Paediatric Committee (PDCO) held its first meeting...
Please login to read the full article.
